A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis

Completed

Conditions studied: Arthritis, Rheumatoid

In brief

This study is to investigate and describe the treatment patterns and effect of tofacitinib indicators for patients with Rheumatoid Arthritis (RA) assessing real world patient data entered in the Corrona RA Registry on or after November 2012

Key facts

Study ID

NCT04721808

Run by

Pfizer

People needed

1712

Starts

2021-01-22

Expected to finish

2021-11-24

Last updated by the study team

2023-09-29

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrolled in the Corrona RA Registry and initiated tofacitinib on or after November 2012
• Initiate tofacitinib (defined as first ever use of tofacitinib) at the Corrona enrollment visit or at a Corrona follow-up visit from November 2012 onward.
• Have CDAI measured at baseline
• Have at least a 6-month follow-up visit and CDAI measured at the 6-month follow-up visit

You may not qualify if…

• There are no exclusion criteria for this study

Where it is running

• Pfizer — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.